[1] |
Mafukidze AT, Calnan M, Furin J. Peripheral neuropathy in persons with tuberculosis. J Clin Tuberc Other Mycobact Dis, 2015, 2:5-11. doi:10.1016/j.jctube.2015.11.002.
doi: 10.1016/j.jctube.2015.11.002.
|
[2] |
Shin SS, Hyson AM, Castañeda C, et al. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2003, 7(4): 347-353.
pmid: 12729340
|
[3] |
《中国防痨杂志》编委会, 中国医疗保健国际交流促进会结核病防治分会全国耐药结核病协作组. 耐药结核病化疗过程中药品不良反应处理的专家共识. 中国防痨杂志, 2019, 41(6):591-603. doi:10.3969/j.issn.1000-6621.2019.06.003.
doi: 10.3969/j.issn.1000-6621.2019.06.003.
|
[4] |
周英凤, 顾莺, 胡雁, 等. JBI循证卫生保健中心对关于不同类型研究的质量评价工具——患病率及分析性横断面研究的质量评价. 护士进修杂志, 2018, 33(3): 219-221. doi:10.16821/j.cnki.hsjx.2018.03.007.
doi: 10.16821/j.cnki.hsjx.2018.03.007.
|
[5] |
王佩鑫, 李宏田, 刘建蒙. 无对照二分类资料的Meta分析方法及Stata实现. 循证医学, 2012, 12(1): 52-55,64. doi:10.3969/j.issn.1671-5144.2012.01.011.
doi: 10.3969/j.issn.1671-5144.2012.01.011.
|
[6] |
Liu NN, Liu L, Li J, et al. Prevalence of and risk factors for dry eye symptom in mainland china: a systematic review and meta-analysis. J Ophthalmol, 2014, 2014: 748654. doi:10.1155/2014/748654.
doi: 10.1155/2014/748654.
|
[7] |
Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis, 2004, 8(11): 1382-1384.
pmid: 15581210
|
[8] |
Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2001, 5(7): 648-655.
pmid: 11467371
|
[9] |
Jacobs TQ, Ross A. Adverse effects profile of multidrug-resistant tuberculosis treatment in a South African outpatient clinic. S Afr Fam Pract, 2012, 54(6): 531-539. doi:10.1080/20786204.2012.10874288.
doi: 10.1080/20786204.2012.10874288.
URL
|
[10] |
Tag El-Din MA, Abd-ElHalim HA, El-Tantawy AM. Adverse reactions among patients being treated for multi-drug resistant tuberculosis in Egypt from July 2006 to January 2009. Egypt J Chest Dis Tuberc, 2015, 64(3): 657-664. doi:10.1016/j.ejcdt.2015.05.011.
doi: 10.1016/j.ejcdt.2015.05.011.
URL
|
[11] |
Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis, 2007, 11(12): 1314-1320.
pmid: 18034952
|
[12] |
Fatima S, Syeda MF, Adla N, et al. Ambispective study of adverse drug reactions in multi-drug resistant tuberculosis patients in Warangal, Telangana. Lung India, 2021, 38(4): 330-337. doi:10.4103/lungindia.lungindia_118_19.
doi: 10.4103/lungindia.lungindia_118_19
pmid: 34259171
|
[13] |
Törün T, Güngör G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2005, 9(12): 1373-1377.
pmid: 16468160
|
[14] |
Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. Medicine (Baltimore), 2017, 96(28): e7482. doi:10.1097/MD.0000000000007482.
doi: 10.1097/MD.0000000000007482.
URL
|
[15] |
张云玲, 韩伊, 张泉, 等. 含贝达喹啉方案治疗耐多药/广泛耐药肺结核的24周不良反应临床分析. 医药导报, 2022, 41(8): 1223-1228. doi:10.3870/j.issn.1004-0781.2022.08.026.
doi: 10.3870/j.issn.1004-0781.2022.08.026.
|
[16] |
张宏, 邝浩斌, 覃红娟, 等. 24例利奈唑胺导致耐多药肺结核患者周围神经炎病例分析. 广州医药, 2019, 50(5): 35-40. doi:10.3969/j.issn.1000-8535.2019.05.009.
doi: 10.3969/j.issn.1000-8535.2019.05.009.
|
[17] |
李元, 秦世炳, 董伟杰, 等. 含利奈唑胺化疗方案治疗术后耐多药脊柱结核患者的效果分析. 中国防痨杂志, 2019, 41(4): 399-404. doi:10.3969/j.issn.1000-6621.2019.04.007.
doi: 10.3969/j.issn.1000-6621.2019.04.007.
|
[18] |
武珊珊, 张越伦, 王巍巍, 等. 耐多药结核病治疗过程中肝损害发生率的Meta分析. 北京大学学报(医学版), 2014, 46(3): 417-423. doi:10.3969/j.issn.1671-167X.2014.03.015.
doi: 10.3969/j.issn.1671-167X.2014.03.015.
|
[19] |
World Health Organization. WHO treatment guidelines for multidrug and rifampicin-resistant tuberculosis. Geneva: World Health Organization, 2018.
|
[20] |
王晓苗, 陈红霞, 童萌萌, 等. 多发性神经炎的中西医研究进展. 新疆中医药, 2018, 36(5):141-144.
|
[21] |
Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000—2004. Int J Tuberc Lung Dis, 2010, 14(3): 275-281.
|
[22] |
Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet, 2005, 365(9456): 318-326. doi:10.1016/S0140-6736(05)17786-1.
doi: 10.1016/S0140-6736(05)17786-1
pmid: 15664227
|
[23] |
高静韬, 刘宇红. 2021年世界卫生组织全球结核病报告要点解读. 河北医科大学学报, 2022, 43(7): 745-749. doi:10.3969/j.issn.1007-3205.2022.07.001.
doi: 10.3969/j.issn.1007-3205.2022.07.001.
|
[24] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10): 1025-1073. doi:10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001.
|
[25] |
刘俊萍, 孙彦波, 张淑兰, 等. 中国耐多药结核不良治疗结局情况的Meta分析. 中国循证医学杂志, 2021, 21(10):1174-1178. doi:10.7507/1672-2531.202106123.
doi: 10.7507/1672-2531.202106123.
|